Nuvation Bio Inc. Class A (NUVB) Peer Comparison

$6.72

$-0.28 (-3.93%)

As on 28-Aug-2026 13:40EDT

Market cap

$2,398 Mln

Revenue (TTM)

$170 Mln

P/E Ratio

--

P/B Ratio

10

Div. Yield

0 %

Edit

	Nuvation Bio Inc. Class A (NUVB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	2,398	17,326	16,614	13,400	12,305
Revenue ($ Mln)	170	2,782	1,054	2,436	670
Net Profit ($ Mln)	-149.83	491.50	755.85	860.62	-319.95
Net Margin (%)	-88.19	17.67	71.69	35.33	-47.79
RoE (%)	-53.55	110.09	--	42.98	-71.14
Price to Earnings	--	36.49	19.38	17.01	--
Price-To-Book	10.04	39.43	10.05	7.27	26.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Nuvation Bio Inc. Class A (NUVB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	169.90	2,782.29	1,054.37	2,435.92	669.50
Cost of Revenue	10.30	1,982.07	103.47	85.67	19.14
Gross Profit	54.46	760.62	588.53	2,236.43	829.45
Operating Expenses	297.23	216.81	841.45	1,378.74	895.93
Operating Profit (EBIT)	-137.63	583.40	109.45	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-149.83	598.92	101.11	1,035.47	-252.08
Provision for Tax	0.00	107.42	-654.74	174.84	20.05
Profit after Tax (Net Income)	-149.83	491.50	755.85	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Nuvation Bio Inc. Class A (NUVB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	253.86	433.86	1,435.90	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	403.88	187.89	384.48	288.55	1,362.63
Current Liabilities	86.76	1,435.43	464.70	361.93	283.35
Total Liabilities	594.82	1,975.47	1,302.02	2,844.42	1,385.30

Assets ($ Mln)

	Nuvation Bio Inc. Class A (NUVB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	18.07	1,006.90	895.24	1,243.41	440.60
Current Assets	726.43	1,050.29	1,389.84	1,250.82	1,671.41
Total Assets	594.82	1,975.47	1,302.02	2,844.42	1,385.30
Total Debt*	252.14	120.10	449.89	165.93	864.07
Net Current Assets	639.68	-385.14	0.00	888.90	1,388.07

Cashflow ($ Mln)

	Nuvation Bio Inc. Class A (NUVB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	-173.43	713.22	51.77	884.27	179.55
Cash Flow from Investing Activities	99.52	-31.14	-8.15	350.44	-129.29
Cash from Financing Activities	202.54	-860.39	34.89	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Nuvation Bio Inc. Class A (NUVB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	-51.90	53.56	-30.01	32.82	-0.17
ROE (%)	-53.55	110.09	163.18	42.98	-71.14
ROA (%)	-19.40	15.64	26.53	29.32	-16.12
EBIT Margin (%)	-76.04	21.13	5.73	31.04	-0.77
Net Margin (%)	-88.19	17.67	71.69	35.33	-47.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Nuvation Bio Inc. Class A (NUVB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	1,083.56	24.67	114.85	9.23	12.22
EBIT Growth (%)	36.11	18.70	136.39	-3.99	93.17
Net Profit Growth (%)	26.16	17.50	378.76	42.89	-115.58
EPS Growth (%)	30.69	26.84	353.27	50.42	-73.87
Book Value Growth (%)	-33.49	164.02	816.12	-0.70	-13.57

Valuation Ratios

	Nuvation Bio Inc. Class A (NUVB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	-15.08	36.06	-59.76	15.79	-2,869.63
Price / Book Value	10.09	35.44	-80.42	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-13.56	28.08	-121.54	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Nuvation Bio Inc. Class A (NUVB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.96	0.00	0.00	0.00	1.77
Short term debt to equity ratio	0.03	0.00	0.05	0.00	0.09
Current Ratio	8.37	0.73	2.99	3.46	5.90
Quick Ratio	8.14	0.73	2.32	3.38	5.90
Interest Coverage	-4.62	--	1.62	--	-1.72

Operating Efficiency Ratios

	Nuvation Bio Inc. Class A (NUVB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	18.67	15.88	21.25	13.74	1.28
Asset Turnover	0.22	0.89	0.37	0.83	0.34
Receivable days	103.51	50.42	85.52	43.48	1.50
Inventory Days	246.85	--	1,056.70	96.17	--
Payable days	342.38	6.26	331.01	147.97	221.81
Cash Conversion Cycle	7.98	--	811.21	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly